further supports the hypothesis that initial response to GLP-1RA treatment may be a good predictor of long-term weight loss. 7 In the present study, our primary aim was to assess the relationship between preoperative GLP-1RA-induced weight changes and the weight change achieved from the start of MWM until 12 months post-bariatric surgery (total weight change [TWC]). A secondary aim was to assess the relationship between weight changes after preoperative GLP-1RA treatment and surgically induced weight changes at 12 months after bariatric surgery. For more detailed background information, please refer to the File S1.
| METHODS
We conducted a retrospective cohort study of patients with Type 2 diabetes mellitus who attended Tier 3 MWM, received GLP-1RA treatment preoperatively, underwent bariatric surgery and were followed up for 12 months post-surgery at a single tertiary centre in the UK.
For full methods, and ethical considerations, please refer to the File S1.
| RESULTS
A total of 45 patients were included in this analysis (gastric band, n = 26; RYGB, n = 16; LSG, n = 3). The study population was mostly composed of middle-aged women with grade III obesity (Table S1 ).
Liraglutide once daily was used in 35 patients, while 10 patients received exenatide twice daily. Eight patients received GLP-1RA treatment postoperatively to improve glycaemic control at the discretion of the treating physician.
Treatment with a GLP-1RA and bariatric surgery resulted in significant weight loss (Table S2) . Please refer to the File S1 for details.
| Relationships between pre-and postoperative weight changes
There was no relationship between GLP-1RA-induced weight change and the weight change induced by bariatric surgery over 12 months, regardless of the type of the surgical procedure (Tables S3 and S4 ).
Using multiple linear regression, greater weight loss (%) before starting GLP-1RA predicted lower weight loss (%) after bariatric surgery after adjustment (please refer to the File S1). however, the contribution of bariatric surgery to TWC was lower in those who lost more weight after GLP-1RA treatment preoperatively.
In addition, we have shown that the impact of GLP-1RA treatment before bariatric surgery does not predict the weight loss achieved after bariatric surgery. There was no difference in post-bariatric surgery weight loss in those who lost weight after GLP-1RA treatment and those who did not lose weight.
There may be several explanations for the lack of relationship between weight changes after GLP-1RA treatment and post-bariatric surgery. One possible explanation is that postoperative weight loss is multifactorial and not only dependent on GLP-1. Hence, response to GLP-1RA treatment on its own may not be able to predict postsurgical weight loss. 8 Another plausible explanation is that GLP-1 levels differ following bariatric surgery and GLP-1RA as bariatric surgery produces higher portal levels of GLP-1 while GLP-1RAs are administered peripherally and not directly into the portal system. 8 In addition, recent evidence suggests that the breakdown products of GLP-1 degradation by DPP-4 might not be as metabolically inactive as has previously been believed. 9 Hence, the increased GLP-1 secretion following bariatric surgery might have different metabolic effects compared with the GLP-1RA treatment. 8 Furthermore, recent rodent studies started to cause doubt about the role of GLP-1 after RYGB or LSG, 10,11 but data collected from humans suggest a central role for GLP-1 in the weight loss after bariatric surgery. 12 One animal study showed that the response to the GLP-1RA exendin-4 predicted some of the metabolic impacts of post-RYGB, particularly in relation to glucose levels, but data from humans are lacking. 13 We found that greater weight loss before or after starting GLP- patients who did not demonstrate any preoperative weight loss.
14 Taken together, these findings suggest that the amount of weight loss that can be achieved in any individual may be predetermined by several biological factors (a weight set-point), 15 and losing weight before surgery reduces the contribution of surgery to the total weight loss, but surgery will still result in significant weight loss regardless of the response (or lack of response) to pharmacological or non-pharmacological interventions before surgery. However, there is a wide variation in individuals' weight set-points and their potential to lose weight, and while the contribution of bariatric surgery to the total weight loss might be lower in patients who lost weight before surgery, the ability of an individual to lose weight (if calculated from start of MWM) can be predicted by their preoperative GLP-1RA-induced weight loss.
The implications are that patients receiving GLP-1RA treatment should be counselled that, although the absolute weight loss after a combined strategy will be more in those who respond to GLP-1RA treatment, the relative contribution of the surgical component may be lower. Thus, this is not a failure of surgery but rather an illustration of how medical and surgical therapy can shift an individual's weight set-point and that those patients who can lose more weight initially with non-surgical interventions are also the ones who can lose most weight overall after bariatric surgery.
Our data also suggest that when assessing the impact of bariatric surgery on weight, the weight loss in the periods preceding surgery needs to be taken into account, and that variation in post-surgical weight loss might reflect variation in preoperative pharmacologically and non-pharmacologically induced weight loss.
The present findings also suggest that there is a need to individualize treatment approaches to obese patients. It seems that some patients may not lose much weight with lifestyle interventions or pharmacotherapy, but will still greatly benefit from bariatric surgery.
In these individuals, bariatric surgery should not be delayed as it is the main mode of treatment. In other individuals who respond well to lifestyle interventions or pharmacotherapy, bariatric surgery will still aid further weight loss and the preoperative weight loss in these individuals seems to predict greater overall weight loss; in these individuals, bariatric surgery will still counteract the usual metabolic adaptations that occur after non-surgical weight loss. The present study has several limitations and strengths; please refer to the File S1 for full details. 
16

